|
|||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
1 | AN ACT concerning health.
| ||||||||||||||||||||||||||||||||||||
2 | Be it enacted by the People of the State of Illinois,
| ||||||||||||||||||||||||||||||||||||
3 | represented in the General Assembly:
| ||||||||||||||||||||||||||||||||||||
4 | Section 5. The Stem Cell Research and Human Cloning | ||||||||||||||||||||||||||||||||||||
5 | Prohibition Act is amended by changing Sections 1, 5, 15, 20, | ||||||||||||||||||||||||||||||||||||
6 | 35, 40, and 45 as follows: | ||||||||||||||||||||||||||||||||||||
7 | (410 ILCS 110/1)
| ||||||||||||||||||||||||||||||||||||
8 | Sec. 1. Short title. This Act may be cited as the Adult | ||||||||||||||||||||||||||||||||||||
9 | Stem Cell Research and Human Cloning Prohibition Act.
| ||||||||||||||||||||||||||||||||||||
10 | (Source: P.A. 95-519, eff. 1-1-08.) | ||||||||||||||||||||||||||||||||||||
11 | (410 ILCS 110/5)
| ||||||||||||||||||||||||||||||||||||
12 | Sec. 5. Policy permitting research. The policy of the State | ||||||||||||||||||||||||||||||||||||
13 | of Illinois shall be as follows: | ||||||||||||||||||||||||||||||||||||
14 | (1) Research involving the derivation and use of human | ||||||||||||||||||||||||||||||||||||
15 | embryonic stem cells, human embryonic germ cells, and human | ||||||||||||||||||||||||||||||||||||
16 | adult stem cells from any source, including cord blood and the | ||||||||||||||||||||||||||||||||||||
17 | reprogramming of adult stem cells somatic cell nuclear | ||||||||||||||||||||||||||||||||||||
18 | transplantation , shall be permitted and the ethical and medical | ||||||||||||||||||||||||||||||||||||
19 | implications of this research shall be given full | ||||||||||||||||||||||||||||||||||||
20 | consideration.
| ||||||||||||||||||||||||||||||||||||
21 | (2) Research involving the derivation and use of human | ||||||||||||||||||||||||||||||||||||
22 | embryonic stem cells, human embryonic germ cells, and human |
| |||||||
| |||||||
1 | adult stem cells , including somatic cell nuclear | ||||||
2 | transplantation, shall be allowed to receive public funds | ||||||
3 | through a program established specifically for the purpose of | ||||||
4 | supporting stem cell research in Illinois under the Department | ||||||
5 | of Public Health.
| ||||||
6 | (3) Adult stem Stem cell research is considered valuable to | ||||||
7 | the health and well-being of all and the unhindered | ||||||
8 | distribution of research materials to all qualified | ||||||
9 | investigators engaged in non-commercial research shall be | ||||||
10 | encouraged within the confines of the law.
| ||||||
11 | (Source: P.A. 95-519, eff. 1-1-08.) | ||||||
12 | (410 ILCS 110/15)
| ||||||
13 | Sec. 15. Department grant program. | ||||||
14 | (a) The Department of Public Health shall develop and | ||||||
15 | administer the Illinois Regenerative Medicine Institute
| ||||||
16 | Program within the Department to provide for the awarding of | ||||||
17 | grants to Illinois medical research institutions. | ||||||
18 | (b) The purposes of the Institute grant program are: | ||||||
19 | (1) to improve the health of the citizens of Illinois | ||||||
20 | through adult stem cell research; | ||||||
21 | (2) to support scientific research in Illinois for | ||||||
22 | which funding from the U.S. government is currently | ||||||
23 | restricted, namely human embryonic stem cell research; | ||||||
24 | (2) (3) to improve the national competitive position of | ||||||
25 | Illinois in the field of regenerative medicine; and |
| |||||||
| |||||||
1 | (3) (4) to promote the translation of stem cell | ||||||
2 | research into clinical practice and the transfer of | ||||||
3 | technology to biomedical and technological industry.
| ||||||
4 | (c) The Department shall adopt rules for the implementation | ||||||
5 | of the Institute grant program, including but not limited to: | ||||||
6 | (1) rules for the solicitation of proposals for grants; | ||||||
7 | (2) rules concerning the eligibility of nonprofit | ||||||
8 | Illinois medical research institutions to receive awards | ||||||
9 | under the Institute grant program; | ||||||
10 | (3) rules for the conduct of competitive and scientific | ||||||
11 | peer review of all proposals submitted under the Institute | ||||||
12 | grant program; | ||||||
13 | (4) rules for the procurement of materials for the | ||||||
14 | conduct of stem cell research, including rules ensuring | ||||||
15 | that persons are empowered to make voluntary and informed | ||||||
16 | decisions to participate or to refuse to participate in | ||||||
17 | such research, and ensuring confidentiality of such | ||||||
18 | decisions; and | ||||||
19 | (5) rules concerning the monitoring of funded research | ||||||
20 | to ensure the researcher is following current best | ||||||
21 | practices with respect to medical ethics, including | ||||||
22 | informed consent of patients and the protection of human | ||||||
23 | subjects.
| ||||||
24 | (Source: P.A. 95-519, eff. 1-1-08.) | ||||||
25 | (410 ILCS 110/20)
|
| |||||||
| |||||||
1 | Sec. 20. Illinois Regenerative Medicine Institute | ||||||
2 | Oversight Committee. | ||||||
3 | (a) The Illinois Regenerative Medicine Institute Oversight | ||||||
4 | Committee shall be established to determine the awards under | ||||||
5 | the Institute grant program. The Committee shall be composed of | ||||||
6 | 7 members appointed by the Governor, with the advice and | ||||||
7 | consent of the Senate. | ||||||
8 | (b) The Committee shall consist of individuals from: | ||||||
9 | (1) professional medical organizations; | ||||||
10 | (2) voluntary health organizations; and | ||||||
11 | (3) for-profit biomedical or biotechnology industry. | ||||||
12 | (c) The Committee shall at all times include at least one | ||||||
13 | member from each of the 3 categories listed in subsection (b) | ||||||
14 | of this Section. | ||||||
15 | (d) No member of the Committee shall be employed by an | ||||||
16 | Illinois medical research institution eligible to receive | ||||||
17 | awards under the Institute grant program.
| ||||||
18 | (e) Upon appointment, the Governor shall designate 3 | ||||||
19 | members to serve a 2-year term and 4 members to serve a 4-year | ||||||
20 | term. The Committee shall designate a Chairperson, | ||||||
21 | Vice-Chairperson, and Secretary. Any vacancy occurring in the | ||||||
22 | membership of the Committee shall be filled in the same manner | ||||||
23 | as the original appointment. | ||||||
24 | (f) No member of the Committee may receive compensation for | ||||||
25 | his or her services, but each member may be reimbursed for | ||||||
26 | expenses incurred in the performance of his or her duties. |
| |||||||
| |||||||
1 | (g) The duties and responsibilities of the Committee shall | ||||||
2 | include, but not be limited to: | ||||||
3 | (1) determination of awards under the Institute grant | ||||||
4 | program, based on recommendations developed under the | ||||||
5 | competitive and scientific peer review process provided | ||||||
6 | for in subdivision (c) (3) of Section 15 of this Act; | ||||||
7 | (2) review of the Department's solicitation and | ||||||
8 | scientific peer review processes to ensure that the | ||||||
9 | statutory purposes of the Institute grant program are met; | ||||||
10 | (3) development, in cooperation with Department staff, | ||||||
11 | general guidelines for the conduct of funded research | ||||||
12 | according to current best practices with respect to medical | ||||||
13 | ethics, in consultation with national and international | ||||||
14 | experts such as the International Society for Stem Cell | ||||||
15 | Research, the California Institute for Regenerative | ||||||
16 | Medicine, the Institute of Medicine, and similar | ||||||
17 | organizations ; and
| ||||||
18 | (4) advice on the future conduct of the Institute grant | ||||||
19 | program. | ||||||
20 | (h) All Institute information concerning medical research | ||||||
21 | shall be confidential and privileged and not subject to | ||||||
22 | disclosure to any person other than Institute personnel.
| ||||||
23 | (Source: P.A. 95-519, eff. 1-1-08.) | ||||||
24 | (410 ILCS 110/35)
| ||||||
25 | Sec. 35. Disclosure of proposed Institute funding |
| |||||||
| |||||||
1 | recipients. | ||||||
2 | (a) Each Institute request to the Committee for approval of | ||||||
3 | proposed stem cell research funding must be accompanied by a | ||||||
4 | written disclosure that identifies the proposed funding | ||||||
5 | recipient and any executives, officers, directors, trustees, | ||||||
6 | fiduciaries, owners, parent company, subsidiaries, affiliates, | ||||||
7 | and institutional or organizational host of the proposed | ||||||
8 | funding recipient. | ||||||
9 | (b) A proposed Institute adult stem cell research funding | ||||||
10 | request shall not be approved by the Committee unless and until | ||||||
11 | the Committee receives the disclosure.
| ||||||
12 | (c) Disclosures provided to the Committee are public | ||||||
13 | records.
| ||||||
14 | (Source: P.A. 95-519, eff. 1-1-08.) | ||||||
15 | (410 ILCS 110/40)
| ||||||
16 | Sec. 40. Cloning prohibited. | ||||||
17 | (a) No person may clone or attempt to clone a human being. | ||||||
18 | For purposes of this Section, "clone or attempt to clone a | ||||||
19 | human being" means human asexual reproduction, accomplished by | ||||||
20 | introducing the genetic material from one or more human somatic | ||||||
21 | cells into a fertilized or unfertilized oocyte whose nuclear | ||||||
22 | material has been removed or inactivated, so as to produce an | ||||||
23 | organism, at any stage of development with a human or | ||||||
24 | predominately human genetic constitution, a process commonly | ||||||
25 | known as somatic cell nuclear transfer to transfer to a uterus |
| |||||||
| |||||||
1 | or attempt to transfer to a uterus anything other than the | ||||||
2 | product of fertilization of an egg of a human female by a sperm | ||||||
3 | of a human male for the purpose of initiating a pregnancy that | ||||||
4 | could result in the creation of a human fetus or the birth of a | ||||||
5 | human being .
| ||||||
6 | (b) (Blank). A person who violates this Section is guilty | ||||||
7 | of a Class 1 felony.
| ||||||
8 | (c) No person may conduct research involving the derivation | ||||||
9 | and use of human embryos, human embryonic stem cells, or human | ||||||
10 | embryonic germ cells. | ||||||
11 | (d) A person who violates this Section is guilty of a Class | ||||||
12 | 1 felony. | ||||||
13 | (Source: P.A. 95-519, eff. 1-1-08.) | ||||||
14 | (410 ILCS 110/45)
| ||||||
15 | Sec. 45. Purchase or sale prohibited. | ||||||
16 | (a) A person may not knowingly, for valuable consideration, | ||||||
17 | purchase or sell embryonic or cadaveric fetal tissue for | ||||||
18 | research purposes.
| ||||||
19 | (b) (Blank). For the purpose of this Section, the giving or | ||||||
20 | receiving of reasonable payment for the removal, processing, | ||||||
21 | disposal, preservation, quality control, storage, | ||||||
22 | transplantation, or implantation of the tissue does not | ||||||
23 | constitute purchase or sale. This Section does not prohibit | ||||||
24 | reimbursement for removal, storage, or transportation of | ||||||
25 | embryonic or cadaveric fetal tissue for research purposes |
| |||||||
| |||||||
1 | pursuant to this Act.
| ||||||
2 | (c) A person who knowingly purchases or sells embryonic or | ||||||
3 | cadaveric fetal tissue for research purposes in violation of | ||||||
4 | subsection (a) of this Section is guilty of a Class A | ||||||
5 | misdemeanor for the first conviction and a Class 4 felony for | ||||||
6 | subsequent convictions.
| ||||||
7 | (Source: P.A. 95-519, eff. 1-1-08.)
| ||||||
8 | Section 99. Effective date. This Act takes effect January | ||||||
9 | 1, 2009.
|